- Home
- DIAX vs CELC Comparison
DIAX vs CELC Comparison
Compare DIAX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- CELC
- Stock Information
- Founded
- DIAX 2005
- CELC 2011
- Country
- DIAX United States
- CELC United States
- Employees
- DIAX N/A
- CELC N/A
- Industry
- DIAX Finance Companies
- CELC Medical Specialities
- Sector
- DIAX Finance
- CELC Health Care
- Exchange
- DIAX Nasdaq
- CELC Nasdaq
- Market Cap
- DIAX 521.1M
- CELC 440.0M
- IPO Year
- DIAX N/A
- CELC 2017
- Fundamental
- Price
- DIAX $14.48
- CELC $51.79
- Analyst Decision
- DIAX
- CELC Strong Buy
- Analyst Count
- DIAX 0
- CELC 6
- Target Price
- DIAX N/A
- CELC $46.50
- AVG Volume (30 Days)
- DIAX 96.6K
- CELC 2.9M
- Earning Date
- DIAX 01-01-0001
- CELC 08-14-2025
- Dividend Yield
- DIAX 7.93%
- CELC N/A
- EPS Growth
- DIAX N/A
- CELC N/A
- EPS
- DIAX N/A
- CELC N/A
- Revenue
- DIAX N/A
- CELC N/A
- Revenue This Year
- DIAX N/A
- CELC N/A
- Revenue Next Year
- DIAX N/A
- CELC N/A
- P/E Ratio
- DIAX N/A
- CELC N/A
- Revenue Growth
- DIAX N/A
- CELC N/A
- 52 Week Low
- DIAX $12.80
- CELC $7.58
- 52 Week High
- DIAX $15.12
- CELC $53.86
- Technical
- Relative Strength Index (RSI)
- DIAX 60.39
- CELC 92.18
- Support Level
- DIAX $14.28
- CELC $38.00
- Resistance Level
- DIAX $14.41
- CELC $53.40
- Average True Range (ATR)
- DIAX 0.11
- CELC 3.33
- MACD
- DIAX 0.01
- CELC 0.92
- Stochastic Oscillator
- DIAX 84.78
- CELC 89.44
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.